Académique Documents
Professionnel Documents
Culture Documents
Erwin Taher
Bag Pat.Klinik
Fak Kedokteran UISU Medan
- Secondary Polycythemia
Relative Polisitemia
- Gaisbock;s syndrome
- sering pada : Pria; middle-aged
(45-55 th); obese; heavy smokers.
- 0,5 0,7 % pop. Normal USA .
-Pemakaian diuretik & smokinginduced high carboxyhemoglobin
level (hipoksia) R.Polisitemia.
-Mild , Hct < 55%
FIGURE 1
APPROACH
TO EVALUATION
OF POLYCYTHEMIA
SECONDARY POLYCYTHEMIA
I. Appropriate increases in erythropoietin production.
TISSUE
HyPOXIA
INCREASED
ERYTHROPOIETIN
PRODUCTION
POLICYTHEMIA
High-Affinity Hemoglobin
-substitusi as.amino pada rantai
globin ( atau )
-Hct < 60% ; WBC / platelet = normal
-P50 O2 50 % -- cenderung menurun
-asimptomatis
-Terapi ( - )
FIGURE 2
OXYGEN HEMOGLOBIN
DISSOCIATION CURVE
Cardiopulmonary Disease
-Pada C.P disease kegagalan pengisian O2
adequate di paru.
-cyanotic congenital heart disease :
(Eisenmengers comp, unventricular heart,
tetralogy of fallot) significant polycythemia
-Hct : 60 75 %
-Hiperviscositas : headache, dizziness, ggn
penglihatan, parasthesia, ggn mental.
-Phlebotomi Pasien dgn Hct > 65% / simptom
dengan replaced saline isotonic
OBESITY-HYPOVENTILATION SYND
-as pickxickian synd
-Charles Dickenss boys/obese (>120%
IBW ) dengan excessive daytime
sleepiness,
-Hipoksemia & Hipercapnea , sbg akibat
blunted ventilatory respone
-Hipoksemia Epo prod >> polisitemia.
POLISITEMIA VERA
Ggn neoplastik yang berasal dari
pluripotensial hemopoietik stemcell
-Case
-SEX
-Age
Patofisiologi :
Pada dewasa normal, sel-sel progenitor erythroid
tidak berproliferasi tanpa pengaruh EPO
Study : Sel progenitor erythroid pat PV yang dikultur
tumbuh dan berkembang menjadi koloni erythron yang
mgd Hb, walaupun tanpa dilakukan penambahan EPO
(Endogenous Erythroid Colony Assay) Dasar
Diagnostik Polisitemia Vera
Study : Sel progenitor erythroid pat PV , hipersensitive
berkembang bila diinduksi dengan berbagai cytokines
( IL-3 ; insulinlike growth factor)
FIGURE 3
BINDING OF ERYTHROPOIETIN
FIGURE 4
TISSUE-OXYGENATION
DELIVERY AND EPO
PRODUCTION